Floatz logo

S-1

Maintenance Therapy

The First Affiliated Hospital with Nanjing Medical UniversityPhase 4 / ApprovedActive
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
81/ 100

Competitive context

8 Active assets in the Maintenance Therapy cohort.

Asset / SponsorPhaseRating
Gilteritinib
The First Affiliated Hospital of Soochow University
Phase 3B
Sorafenib
The First Affiliated Hospital of Soochow University
Phase 3B
VINCRISTINE SULFATE
Fudan University
Phase 2CCC
Zanubrutinib
Fudan University
Phase 2CCC
Inno-206
Fudan University
Phase 2CCC
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Fudan University
Phase 2CCC
PREDNISONE TABLETS
Fudan University
Phase 2CCC
Cyclophosphamide
Fudan University
Phase 2CCC

Same molecule, other indications

S-1 is also rated in:

malignant pancreatic neoplasmDormant
BB
Indicative ·
71 / 100
View asset →
Gastric NeoplasmDormant
BB
Indicative ·
69 / 100
View asset →
malignant pancreatic neoplasmDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →